Abstract
Introduction: Increasing evidence indicates that non-coding RNAs (ncRNAs) are aberrantly expressed and/or functionally deregulated in hematological malignancies, including multiple myeloma. Harnessing these abnormalities by either replacing or inhibiting ncRNAs is emerging as novel therapeutic option. Areas covered: We review the recent remarkable advancement in the understanding of the biological functions of human ncRNAs in multiple myeloma, including the biogenesis, the mechanisms of expression, the relevance as biomarkers, and mostly, the therapeutic potential. Special emphasis is given to microRNAs, the best characterized class of ncRNAs. Expert opinion: An improved understanding of the role of ncRNAs in multiple myeloma would provide valuable information about key cancer-promoting pathways and might be highly useful for diagnostic and prognostic assessments. This knowledge might also lead to advancement in the management of multiple myeloma through the development of novel personalized ncRNA-based therapies.
| Original language | English |
|---|---|
| Journal | Expert Opinion on Biological Therapy |
| Volume | 13 |
| Issue number | SUPPL.1 |
| DOIs | |
| Publication status | Published - Jun 2013 |
Fingerprint
Keywords
- MicroRNA
- MiRNA
- MiRNA therapeutics
- Multiple myeloma
- Non coding RNA
ASJC Scopus subject areas
- Pharmacology
- Clinical Biochemistry
- Drug Discovery
Cite this
Non-coding RNA : A novel opportunity for the personalized treatment of multiple myeloma. / Amodio, Nicola; Di Martino, Maria Teresa; Neri, Antonino; Tagliaferri, Pierosandro; Tassone, Pierfrancesco.
In: Expert Opinion on Biological Therapy, Vol. 13, No. SUPPL.1, 06.2013.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Non-coding RNA
T2 - A novel opportunity for the personalized treatment of multiple myeloma
AU - Amodio, Nicola
AU - Di Martino, Maria Teresa
AU - Neri, Antonino
AU - Tagliaferri, Pierosandro
AU - Tassone, Pierfrancesco
PY - 2013/6
Y1 - 2013/6
N2 - Introduction: Increasing evidence indicates that non-coding RNAs (ncRNAs) are aberrantly expressed and/or functionally deregulated in hematological malignancies, including multiple myeloma. Harnessing these abnormalities by either replacing or inhibiting ncRNAs is emerging as novel therapeutic option. Areas covered: We review the recent remarkable advancement in the understanding of the biological functions of human ncRNAs in multiple myeloma, including the biogenesis, the mechanisms of expression, the relevance as biomarkers, and mostly, the therapeutic potential. Special emphasis is given to microRNAs, the best characterized class of ncRNAs. Expert opinion: An improved understanding of the role of ncRNAs in multiple myeloma would provide valuable information about key cancer-promoting pathways and might be highly useful for diagnostic and prognostic assessments. This knowledge might also lead to advancement in the management of multiple myeloma through the development of novel personalized ncRNA-based therapies.
AB - Introduction: Increasing evidence indicates that non-coding RNAs (ncRNAs) are aberrantly expressed and/or functionally deregulated in hematological malignancies, including multiple myeloma. Harnessing these abnormalities by either replacing or inhibiting ncRNAs is emerging as novel therapeutic option. Areas covered: We review the recent remarkable advancement in the understanding of the biological functions of human ncRNAs in multiple myeloma, including the biogenesis, the mechanisms of expression, the relevance as biomarkers, and mostly, the therapeutic potential. Special emphasis is given to microRNAs, the best characterized class of ncRNAs. Expert opinion: An improved understanding of the role of ncRNAs in multiple myeloma would provide valuable information about key cancer-promoting pathways and might be highly useful for diagnostic and prognostic assessments. This knowledge might also lead to advancement in the management of multiple myeloma through the development of novel personalized ncRNA-based therapies.
KW - MicroRNA
KW - MiRNA
KW - MiRNA therapeutics
KW - Multiple myeloma
KW - Non coding RNA
UR - http://www.scopus.com/inward/record.url?scp=84879592480&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879592480&partnerID=8YFLogxK
U2 - 10.1517/14712598.2013.796356
DO - 10.1517/14712598.2013.796356
M3 - Article
C2 - 23692413
AN - SCOPUS:84879592480
VL - 13
JO - Expert Opinion on Biological Therapy
JF - Expert Opinion on Biological Therapy
SN - 1471-2598
IS - SUPPL.1
ER -